Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC reduced its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 16.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 306,762 shares of the company’s stock after selling 58,282 shares during the period. Kura Oncology accounts for about 3.8% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 14th biggest holding. Ally Bridge Group NY LLC owned about 0.40% of Kura Oncology worth $6,316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in KURA. SG Americas Securities LLC bought a new position in Kura Oncology in the 1st quarter worth approximately $110,000. Cape Investment Advisory Inc. acquired a new stake in Kura Oncology in the fourth quarter worth approximately $176,000. Saxon Interests Inc. acquired a new stake in Kura Oncology in the first quarter worth approximately $201,000. Entropy Technologies LP bought a new position in Kura Oncology during the 1st quarter valued at $218,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Kura Oncology by 81.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,617 shares of the company’s stock valued at $333,000 after purchasing an additional 7,027 shares during the period.

Wall Street Analysts Forecast Growth

KURA has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus dropped their target price on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.60.

Kura Oncology Price Performance

KURA stock opened at $20.95 on Monday. Kura Oncology, Inc. has a one year low of $7.41 and a one year high of $24.17. The firm has a 50-day moving average of $20.25 and a two-hundred day moving average of $20.61. The firm has a market capitalization of $1.60 billion, a PE ratio of -9.65 and a beta of 0.84. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts forecast that Kura Oncology, Inc. will post -2.45 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.